文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗慢性自发性荨麻疹:3期LIBERTY-CSU CUPID随机临床试验

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2026-01-01

LIBERTY-CSU CUPID-C是一项随机、安慰剂对照、双盲、24周3期试验,纳入151例抗IgE初治且H1-AH控制不佳的CSU患者。度普利尤单抗较安慰剂显著改善第24周ISS7和UAS7,安全性与已知特征一致,汇总CUPID-A和-C数据进一步支持疗效。

要点

  • 度普利尤单抗显著降低抗IgE初治CSU患者第24周瘙痒和风团严重度。
  • CUPID-C结果与CUPID-A一致,汇总数据支持度普利尤单抗疗效。
  • 安全性总体与度普利尤单抗已知安全性特征一致。

核心结论

  • CUPID-C证实CUPID-A findings,汇总数据显示度普利尤单抗显著降低抗IgE初治且H1-AH控制不佳CSU患者的荨麻疹活动度。

研究设计与样本

  • LIBERTY-CSU CUPID-C(2022-2024)为随机、安慰剂对照、双盲、24周3期试验,设计与CUPID-A(2019-2021)相同。
  • 两项试验在亚洲、欧洲、北美和南美10个国家开展,纳入6至80岁抗IgE初治且H1-AH控制不佳的CSU患者。
  • CUPID-C分析纳入151例参与者,平均(SD)年龄44.7(16.9)岁,女性106例(70.2%)。
  • CUPID-A和-C汇总分析共289例参与者。

主要发现

  • CUPID-A和-C汇总数据显示UAS7和ISS7改善更明显。
  • 汇总分析中,度普利尤单抗组77例(53.5%)和安慰剂组81例(55.9%)报告治疗中出现的不良事件。

关键数值与推荐

  • CUPID-C中77例(51%)在基线时使用高于推荐剂量的H1-AH。
  • CUPID-C中90例(59.6%)基线UAS7≥28。

临床怎么用

  • 对于抗IgE初治且H1-AH控制不佳的CSU患者,度普利尤单抗可显著改善瘙痒和风团严重度。
  • 度普利尤单抗安全性总体与已知特征一致,可作为该类患者的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic spontaneous urticaria (CSU) is an inflammatory disease characterized by recurrent pruritic hives and/or angioedema. Many patients with CSU remain symptomatic despite standard-of-care, histamine 1-receptor antagonist (H1-AH) treatment. Dupilumab blocks IL-4/IL-13 signaling and is approved in multiple disease states associated with type 2 inflammation. In the phase 3 LIBERTY-CSU CUPID-A trial, dupilumab significantly reduced itch and hives severity in anti-immunoglobulin E (IgE)-naive patients with CSU uncontrolled with H1-AH. However, a replicate trial (CUPID-C) was required per US Food and Drug Administration registration requirements. OBJECTIVE: To further evaluate the efficacy and safety of dupilumab vs placebo in anti-IgE-naive patients with CSU uncontrolled by H1-AH. DESIGN, SETTING, AND PARTICIPANTS: The LIBERTY-CSU CUPID-C (2022-2024) was a randomized, placebo-controlled, double-blind, 24-week phase 3 trial using the same trial design as CUPID-A (2019-2021). CUPID-A and CUPID-C were performed in 10 countries in Asia, Europe, and North and South America with anti-IgE-naive patients aged 6 to 80 years with CSU uncontrolled with H1-AH. Data were analyzed from August to September 2024. INTERVENTIONS: Dupilumab or placebo. MAIN OUTCOMES AND MEASURES: In CUPID-C and pooled CUPID-A and -C analyses, change from baseline at week 24 in Itch Severity Score over 7 days (ISS7) or Urticaria Activity Score over 7 days (UAS7), with the other as a key secondary end point, per regional regulatory requirements. RESULTS: The CUPID-C analysis included 151 participants (mean [SD] age, 44.7 [16.9] years; 106 females [70.2%]), of whom 77 (51%) were taking H1-AH at a dosage higher than recommended, and 90 (59.6%) had a baseline UAS7 of 28 or greater. Significant improvements in ISS7 and UAS7 were observed with dupilumab vs placebo at week 24. Least squares mean (SE) changes were -8.64 (1.41) vs -6.10 (1.40), respectively (difference: -2.54 points [95% CI, -4.65 to -0.43]; P = .02) for ISS7 and -15.86 (2.66) vs -11.21 (2.65), respectively (difference: -4.65 points [95% CI, -8.65 to -0.65]; P = .02) for UAS7. CUPID-A and -C combined data (289 participants) demonstrated greater improvements in UAS7 and ISS7. Safety outcomes were generally consistent with the known dupilumab safety profile; 77 patients (53.5%) taking dupilumab vs 81 patients (55.9%) taking placebo reported treatment-emergent adverse events in the pooled analysis. CONCLUSIONS AND RELEVANCE: The CUPID-C randomized clinical trial confirmed CUPID-A findings, and pooled data demonstrated dupilumab significantly reduced urticaria activity by reducing itch and hives severity in anti-IgE-naive patients with CSU who remained symptomatic despite the use of H1-AH. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04180488.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Casale TB, Saini SS, Ben-Shoshan M, et al. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. JAMA Dermatol. 2026. PMID: 41706458. doi:10.1001/jamadermatol.2025.6023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。